Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
Source: View publication →
In the prespecified 5-year analysis of the RELATIVITY-047 trial, dual inhibition with relatlimab and nivolumab demonstrated sustained, clinically significant improvements in progression-free, overall, and melanoma-specific survival compared to nivolumab alone in patients with advanced melanoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
This 5-year update solidifies nivolumab plus relatlimab as a standard-of-care first-line treatment for metastatic or unresectable melanoma, proving that the initial benefits of dual PD-1 and LAG-3 blockade translate into durable long-term survival. The biomarker findings offer critical mechanistic insights, suggesting that elevated LAG-3 + CD8 cells drive primary resistance to PD-1 monotherapy, which can be successfully overcome by the upfront addition of relatlimab.
Historical Context
The RELATIVITY-047 trial originally made history as the first phase 3 study to validate LAG-3 as a therapeutic immune checkpoint, leading to the FDA approval of the fixed-dose combination of nivolumab and relatlimab in 2022. Much like the CheckMate 067 trial did for CTLA-4/PD-1 blockade (ipilimumab plus nivolumab), this prespecified 5-year analysis was highly anticipated to confirm whether the initial progression-free survival benefits of LAG-3/PD-1 blockade would translate into durable, long-term overall survival without compounding the safety profile.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of relatlimab, and why does combining it with a PD-1 inhibitor like nivolumab produce a synergistic anti-tumor effect in advanced melanoma?
Key Response
Relatlimab is a monoclonal antibody that blocks LAG-3 (Lymphocyte-activation gene 3), an inhibitory immune checkpoint receptor expressed on exhausted T-cells. Combining LAG-3 blockade with PD-1 blockade (nivolumab) targets two distinct immune checkpoint pathways, leading to synergistic T-cell reactivation, enhanced cytokine production, and the ability to overcome resistance to PD-1 monotherapy.
When evaluating a patient with newly diagnosed, unresectable advanced melanoma, how should the 5-year survival and toxicity data from RELATIVITY-047 influence your choice between relatlimab-nivolumab, ipilimumab-nivolumab, and anti-PD1 monotherapy?
Key Response
The choice requires balancing efficacy and immune-related adverse events (irAEs). Relatlimab-nivolumab offers superior progression-free and overall survival compared to nivolumab alone, with a more favorable toxicity profile (fewer grade 3/4 irAEs) than the ipilimumab-nivolumab combination. This makes it an ideal first-line option for patients who need dual-checkpoint efficacy but might not tolerate the high toxicity of anti-CTLA-4 therapy.
The RELATIVITY-047 biomarker analysis evaluates outcomes based on LAG-3 and PD-L1 expression. How should a medical oncology fellow interpret the utility of LAG-3 expression as a predictive biomarker for patient selection in clinical practice?
Key Response
While the trial data shows that patients with LAG-3 expression >= 1% have higher objective response rates, the 5-year analysis indicates that patients with LAG-3 expression < 1% still derive a clinically meaningful survival benefit from the combination over nivolumab alone. Therefore, LAG-3 expression is prognostic but not strictly predictive enough to exclude patients from therapy, meaning it is not currently used as a mandatory companion diagnostic for prescribing the combination.
Given the sustained 5-year melanoma-specific survival benefit of relatlimab-nivolumab, how does this long-term data shift the clinical paradigm and teaching algorithms regarding the use of CTLA-4 inhibitors (ipilimumab) in the first-line setting?
Key Response
The robust 5-year data solidifies relatlimab-nivolumab as a standard first-line option. Attendings must teach that while ipilimumab-nivolumab remains crucial for specific high-risk subsets (e.g., active brain metastases, which were excluded from RELATIVITY-047), relatlimab-nivolumab's durable efficacy and lower toxicity profile largely replaces ipilimumab-nivolumab for the average patient with asymptomatic advanced melanoma, fundamentally changing first-line treatment algorithms.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In analyzing the 5-year overall survival data of RELATIVITY-047, what are the primary statistical challenges introduced by informative censoring and subsequent therapies, and how can researchers adjust for these to isolate the true long-term effect of the initial therapy?
Key Response
In 5-year oncology analyses, patients often drop out, cross over, or receive subsequent targeted therapies or immunotherapies, heavily confounding Overall Survival (OS) endpoints. Researchers must critically evaluate statistical methods such as inverse probability of censoring weighting (IPCW) or analyze Progression-Free Survival 2 (PFS2) to adjust for these post-progression variables and accurately determine the long-term benefit attributable solely to the initial relatlimab-nivolumab combination.
As a peer reviewer assessing this 5-year update, how does the absence of a direct active comparator arm containing ipilimumab-nivolumab impact the editorial significance and clinical translation of this study for the evolving melanoma landscape?
Key Response
A critical reviewer would flag that while RELATIVITY-047 proves superiority over nivolumab monotherapy, the most pressing clinical dilemma today is choosing between relatlimab-nivolumab and ipilimumab-nivolumab. The lack of a head-to-head comparison limits definitive conclusions on the optimal dual-checkpoint blockade. Editors must ensure authors do not overstate the combination's superiority across all treatment paradigms, specifically acknowledging this trial design limitation.
Based on the 5-year sustained efficacy and safety data from RELATIVITY-047, what is the level of evidence for recommending relatlimab-nivolumab as a preferred first-line systemic therapy, and how should NCCN and ESMO guidelines position this relative to BRAF/MEK inhibitors in BRAF-mutated patients?
Key Response
This represents Level 1 evidence (long-term data from a Phase 3 RCT). Guidelines should firmly position relatlimab-nivolumab as a Category 1 preferred first-line regimen for wild-type melanoma. For BRAF V600-mutated melanoma, guidelines should continue to favor upfront immunotherapy (like relatlimab-nivolumab) over targeted therapy due to the durability of immune responses demonstrated at 5 years, updating flowcharts to reflect its established long-term superiority over PD-1 monotherapy.
Clinical Landscape
Noteworthy Related Trials
CheckMate 067 Trial
Tested
Nivolumab plus Ipilimumab or Nivolumab alone
Population
Previously untreated advanced melanoma patients
Comparator
Ipilimumab alone
Endpoint
Progression-free survival and overall survival
KEYNOTE-006 Trial
Tested
Pembrolizumab
Population
Patients with advanced melanoma
Comparator
Ipilimumab
Endpoint
Progression-free survival and overall survival
CheckMate 066 Trial
Tested
Nivolumab
Population
Previously untreated BRAF wild-type advanced melanoma patients
Comparator
Dacarbazine
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis